Celgene Corporation (CELG) : Handelsbanken Fonder Ab scooped up 14,000 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 15, 2016. The investment management firm now holds a total of 369,310 shares of Celgene Corporation which is valued at $37,928,137.Celgene Corporation makes up approximately 1.50% of Handelsbanken Fonder Ab’s portfolio.
Other Hedge Funds, Including , Nisa Investment Advisors reduced its stake in CELG by selling 1,868 shares or 0.82% in the most recent quarter. The Hedge Fund company now holds 226,413 shares of CELG which is valued at $23,252,615. Celgene Corporation makes up approx 0.30% of Nisa Investment Advisors’s portfolio.Legacy Private Trust reduced its stake in CELG by selling 8,803 shares or 18.14% in the most recent quarter. The Hedge Fund company now holds 39,721 shares of CELG which is valued at $4,079,347. Celgene Corporation makes up approx 0.58% of Legacy Private Trust’s portfolio.Renaissance Investment Group reduced its stake in CELG by selling 22 shares or 0.06% in the most recent quarter. The Hedge Fund company now holds 38,559 shares of CELG which is valued at $3,960,009. Celgene Corporation makes up approx 1.89% of Renaissance Investment Group’s portfolio.Hall Laurie J Trustee reduced its stake in CELG by selling 230 shares or 1.39% in the most recent quarter. The Hedge Fund company now holds 16,355 shares of CELG which is valued at $1,664,285. Celgene Corporation makes up approx 1.07% of Hall Laurie J Trustee’s portfolio.Indiana Trust Investment Management Co reduced its stake in CELG by selling 160 shares or 0.92% in the most recent quarter. The Hedge Fund company now holds 17,246 shares of CELG which is valued at $1,728,912. Celgene Corporation makes up approx 0.91% of Indiana Trust Investment Management Co’s portfolio.
Celgene Corporation closed down -0.15 points or -0.15% at $102.7 with 25,30,186 shares getting traded on Monday. Post opening the session at $102.85, the shares hit an intraday low of $102.01 and an intraday high of $103.38 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.